Stock Events

Stock Events

Phio Pharmaceuticals 

$1.1800
58
-$0.03-2.48% Friday 20:00
-$0.01-0.85%Friday 23:12After hours

Statistics

Day High
1.181
Day Low
1.181
52W High
4.19
52W Low
0.813
Volume
1,444
Avg. Volume
-
Mkt Cap
13.71M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-4.14
-2.84
-1.54
-0.24
Expected EPS
-0.35
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-8.7MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHIO. It's not an investment recommendation.
Amazon
9
AMZN
NVIDIA
9
NVDA
Microsoft
8
MSFT
AMD
8
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap25.28B
Moderna is a leader in mRNA technology, competing in the broader field of genetic medicines, similar to Phio's RNAi therapeutics approach.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.6B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, directly competing with Phio's core technology and product pipeline.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap12.24B
Arrowhead Pharmaceuticals focuses on developing RNAi therapeutics for a variety of diseases, making it a direct competitor.
Ionis Pharmaceuticals
IONS
Mkt Cap9.51B
Ionis Pharmaceuticals is a leader in RNA-targeted drug discovery and development, competing in the same space as Phio.
Sarepta Therapeutics
SRPT
Mkt Cap1.91B
Sarepta Therapeutics focuses on RNA-based therapies, particularly for rare diseases, overlapping with Phio's therapeutic areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap13.04B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals, including RNA-based products, competing in the genetic disease market.
CRISPR Therapeutics
CRSP
Mkt Cap5.18B
CRISPR Therapeutics is focused on developing gene-based medicines, including CRISPR/Cas9 technology, which competes in the broader genetic medicine space.
Intellia Therapeutics
NTLA
Mkt Cap1.67B
Intellia Therapeutics is a leading developer of CRISPR gene editing, competing in the genetic medicine field alongside companies like Phio.

About

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
Show more...
CEO
Robert L. Bitterman
Employees
6
Country
United States
ISIN
US71880W5013
WKN
000A3D451

Listings

MU
DE
44R0.MU
XNAS
US
PHIO
BOATS
BOATS
PHIO.BOATS

0 Comments

Share your thoughts

FAQ

What is Phio Pharmaceuticals stock price today?▼
The current price of PHIO is $1.18 USD — it has decreased by -2.48% in the past 24 hours. Watch Phio Pharmaceuticals stock price performance more closely on the chart.
What is Phio Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Phio Pharmaceuticals stocks are traded under the ticker PHIO.
Is Phio Pharmaceuticals stock price growing?▼
PHIO stock has risen by +8.26% compared to the previous week, the month change is a +11.32% rise, over the last year Phio Pharmaceuticals has showed a -43.54% decrease.
What is Phio Pharmaceuticals market cap?▼
Today Phio Pharmaceuticals has the market capitalization of 13.71M
When is the next Phio Pharmaceuticals earnings date?▼
Phio Pharmaceuticals is going to release the next earnings report on November 05, 2026.
What were Phio Pharmaceuticals earnings last quarter?▼
PHIO earnings for the last quarter are -0.36 USD per share, whereas the estimation was -0.36 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Phio Pharmaceuticals revenue for the last year?▼
Phio Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Phio Pharmaceuticals net income for the last year?▼
PHIO net income for the last year is -8.7M USD.
How many employees does Phio Pharmaceuticals have?▼
As of August 22, 2026, the company has 6 employees.
In which sector is Phio Pharmaceuticals located?▼
Phio Pharmaceuticals operates in the Health & Wellness sector.
When did Phio Pharmaceuticals complete a stock split?▼
The last stock split for Phio Pharmaceuticals was on July 05, 2024 with a ratio of 1:9.
Where is Phio Pharmaceuticals headquartered?▼
Phio Pharmaceuticals is headquartered in KING OF PRUSSIA, United States.